drugset / Trial / NCT01615510

Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models

NCT01615510

Phase 1 Terminated 24 enrolled University Hospital Schleswig-Holstein
RandomizedCrossoverTriple-blindTreatment

Summary

MOR-NRI like Tapentadol are expected to reduce signs and symptoms of central sensitisation besides effectively reducing pain intensity in pain. Human pain surrogate models can serve in this proof-of-concept study to further elucidate this assumption.

Timeline

Start
2012-10
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapentadol Small molecule 100 mg Oral

Indications